Concomitant Azole Initiation Decreases Time to Stable Goal Sirolimus Concentrations in Pediatric Allogeneic...

Area of Science:

• Pharmacology
• Transplantation Medicine
• Drug Interactions

Background:

• Sirolimus pharmacokinetics exhibit significant variability.
• Interactions with azole antifungals can disrupt therapeutic sirolimus concentrations.
• Suboptimal sirolimus levels increase the risk of transplant-related complications.

Purpose of the Study:

• To compare the time to achieve stable, goal sirolimus concentrations.
• To evaluate the impact of concomitant versus delayed azole initiation on sirolimus pharmacokinetics.
• To assess the rate of concentrations outside the goal range based on initiation timing.

Main Methods:

• Prospective study comparing two groups: concomitant azole/sirolimus initiation vs. delayed azole initiation.
• Measured time to attainment of stable goal sirolimus concentrations.
• Adjusted for patient demographics (age, sex, race) in statistical analysis.

Main Results:

• The concomitant group achieved stable goal sirolimus concentrations faster (median 6.0 days) than the delayed group (median 8.0 days).
• Concomitant initiation was associated with significantly earlier attainment of stable concentrations (hazard ratio: 0.27, P<0.001).
• The delayed group had a nearly twofold higher rate of concentrations outside the goal range (P<0.001).

Conclusions:

• Concomitant initiation of sirolimus and azole antifungals accelerates the achievement of stable therapeutic sirolimus concentrations.
• This strategy may improve therapeutic drug monitoring and reduce complications post-allogeneic cell transplant.
• Simultaneous initiation is a potentially beneficial approach for managing sirolimus therapy in transplant recipients requiring azole antifungals.